Pamrevlumab plus nab-paclitaxel/gemcitabine (Pam + GA) as first- and second-line therapy in metastatic pancreatic cancer (mPDAC): Results from Precision Promise (PrP ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback